Oppenheimer initiated coverage on Crinetics Pharmaceuticals with a new price target
$CRNX
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Crinetics Pharmaceuticals with a rating of Outperform and set a new price target of $40.00